Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07480369

Vegan Diet and Immune-Inflammatory Outcomes in Asthma and Healthy Adults

This randomized controlled study evaluates the effects of a balanced vegan diet compared with a balanced omnivorous diet on inflammatory and immune response markers and clinical asthma parameters in healthy adults and individuals with mild to moderate asthma, aged 18 to 50. Participants will follow assigned dietary plans for 12 weeks with dietitian support delivered via digital tools.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

This prospective, randomized, controlled study aims to evaluate the effects of a balanced vegan diet on inflammatory and immune response markers, clinical asthma parameters, and metabolic profile in healthy adults and patients with mild to moderate asthma. The study will enroll participants aged 18 to 50 years, who will be randomly assigned to either a vegan diet intervention group or a control group following an omnivorous diet for 12 weeks.

Dietary interventions will be individually tailored by a clinical dietitian according to current national nutrition guidelines. To ensure safety and standardization, all participants will receive vitamin D supplementation (2000 IU/day), and participants in the vegan group will additionally receive vitamin B₁₂ supplementation (25-100 µg/day or weekly equivalent). Adherence to the diet will be monitored through weekly online consultations, 3-day food diaries, and digital tools.

Assessments will be performed at baseline and after 12 weeks of intervention. Evaluated parameters will include:

  • Inflammatory markers: hsCRP, IL-4, IL-5, IL-13, TNF-α
  • Immune function markers: lymphocyte subpopulations (CD4+, CD8+, CD4+/CD8+ ratio, Treg cells by flow cytometry/ELISA) and immunoglobulins (IgE, IgA, IgG, IgG1-IgG4)
  • Respiratory function: fractional exhaled nitric oxide (FeNO), spirometry
  • Anthropometric and body composition measures: body weight, body mass index (BMI), waist circumference, waist-to-hip ratio, bioimpedance body composition analysis
  • Lipid profile: total cholesterol, HDL, LDL, non-HDL cholesterol, triglycerides
  • Asthma symptom control: Asthma Control Test (ACT) scores The planned sample size is 280 participants, distributed across four groups (n=70 per group): healthy - omnivorous diet, healthy - vegan diet, asthma - omnivorous diet, asthma - vegan diet. However, an initial pilot phase will be conducted to assess feasibility and refine study procedures before full-scale recruitment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For all groups:

  • Aged 18-30 years
  • Willing to adhere to assigned dietary plan (vegan or omnivorous) for 12 weeks
  • Non-smoker for at least 5 years
  • Body mass index (BMI) between 18.5 and 24.9 kg/m2

For the asthma group:

  • Clinical diagnosis of mild or moderate asthma (GINA criteria), made at least 12 months before enrollment
  • Stable asthma status (no exacerbations or changes in therapy within the past 3 months)
  • No change in pharmacotherapy during the study period

Exclusion criteria

  • Use of systemic corticosteroids (oral or intravenous) within the past 3 months
  • Ongoing biological therapy for asthma (e.g., anti-IgE, anti-IL-5, anti-IL-4R)
  • Severe asthma as per GINA criteria
  • Recent asthma exacerbation requiring hospitalization or steroid burst (<3 months)
  • Presence of other chronic autoimmune or inflammatory diseases
  • Pregnancy or lactation
  • Active infection or acute illness at the time of recruitment
  • Adherence to specialized exclusion diets (e.g., ketogenic, low-FODMAP)
  • History of eating disorders
  • Inability or unwillingness to participate in follow-up visits or comply with the protocol

Treatment and study plan

Omnivorous diet

Behavioral

Participants will follow an individually planned, nutritionally adequate, isocaloric omnivorous diet for 12 weeks. Diet plans will be prepared by a clinical dietitian. Adherence will be monitored 3-day food diaries, weekly remote consultations, and digital tools. Participants will receive vitamin D supplementation (2000 IU/day).

Vegan diet

Behavioral

Participants will follow an individually planned, nutritionally adequate isocaloric vegan diet for 12 weeks. Diet plans will be prepared by a clinical dietitian. Adherence will be monitored 3-day food diaries, weekly remote consultations, and digital tools. Participants will receive vitamin D supplementation (2000 IU/day) and vitamin B12 supplementation according to standard recommendations.

Primary outcomes

  1. Change in hsCRP levels

    Time frame: Baseline and after week 12

    Change in serum high-sensitivity C-reactive protein (hsCRP) concentration as a marker of systemic inflammation.

  2. Change in IL-4 levels

    Time frame: Baseline and after week 12

    Change in serum interleukin-4 (IL-4) levels as an indicator of Th2-mediated inflammatory response.

  3. Change in IL-5 levels

    Time frame: Baseline and after week 12

    Change in serum interleukin-5 (IL-5) levels as a marker of eosinophilic inflammation.

  4. Change in IL-13 levels

    Time frame: Baseline and after week 12

    Change in serum interleukin-13 (IL-13) levels associated with allergic airway inflammation.

  5. Change in TNF-α levels

    Time frame: Baseline and after week 12

    Change in tumor necrosis factor alpha (TNF-α) levels as a marker of systemic inflammatory activity.

Secondary outcomes

  1. Change in lymphocyte subpopulations

    Time frame: Baseline and after week 12

    Changes in lymphocyte subpopulations including CD4+, CD8+, CD4+/CD8+ ratio, and Treg cells

  2. Change in serum IgE levels

    Time frame: Baseline and after week 12

    Change in immunoglobulin E concentration associated with allergic inflammation.

  3. Change in serum IgA levels

    Time frame: Baseline and after week 12

    Change in immunoglobulin A concentration reflecting mucosal immune function.

  4. Change in serum IgG levels

    Time frame: Baseline and after week 12

    Change in total immunoglobulin G concentration.

  5. Change in IgG subclasses

    Time frame: Baseline and after week 12

    Changes in IgG subclasses including IgG1, IgG2, IgG3 and IgG4.

  6. Change in fractional exhaled nitric oxide (FeNO)

    Time frame: Baseline and after week 12

    Measurement of airway inflammation assessed using fractional exhaled nitric oxide.

  7. Change in spirometry parameters

    Time frame: Baseline and after week 12

    Changes in pulmonary function parameters (FEV1, FVC, FEV1/FVC)

  8. Change in Asthma Control Test (ACT) score

    Time frame: Baseline and after week 12

    Change in asthma symptom control measured using the Asthma Control Test (ACT). The ACT is a validated 5-item questionnaire with scores ranging from 5 to 25, where higher scores indicate better asthma control.

  9. Change in lipid profile

    Time frame: Baseline and after week 12

    Changes in total cholesterol, HDL-cholesterol, LDL-cholesterol, non-HDL cholesterol, and triglycerides

  10. Change in body weight

    Time frame: Baseline and after week 12

    Change in body weight measured in kilograms during the intervention.

  11. Change in body mass index (BMI)

    Time frame: Baseline and after week 12

    Change in BMI calculated from weight and height (kg/m²).

  12. Change in waist circumference

    Time frame: Baseline and after week 12

    Change in waist circumference as a measure of central adiposity

  13. Change in waist-to-hip ratio (WHR)

    Time frame: Baseline and after week 12

    Change in waist-to-hip ratio as a measure of body fat distribution.

  14. Change in body composition

    Time frame: Baseline and after week 12

    Changes in fat mass and lean mass assessed by bioimpedance analysis

Sponsors and collaborators

Lead sponsor

Medical University of Gdansk

Other

Registry information

Official study title

The Effect of a Vegan Diet on Inflammatory and Immune Biomarkers in Adult Patients With Asthma and in Healthy Individuals: A Randomized Controlled Trial

Acronym: VEGASTHMA

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Mar 18, 2026
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.